BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 9414302)

  • 1. Lymphoma cell burden in progenitor cell grafts measured by competitive polymerase chain reaction: less than one log difference between bone marrow and peripheral blood sources.
    Léonard BM; Hétu F; Busque L; Gyger M; Bélanger R; Perreault C; Roy DC
    Blood; 1998 Jan; 91(1):331-9. PubMed ID: 9414302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone marrow versus peripheral blood progenitor cells CD34 selection in patients with non-Hodgkin's lymphomas: different levels of tumor cell reduction. Implications for autografting.
    Lopez M; Lemoine FM; Firat H; Fouillard L; Laporte JP; Lesage S; Isnard F; Stachowiak J; Ferrer-Le Coeur F; Morel P; Najman A; Douay L; Gorin NC
    Blood; 1997 Oct; 90(7):2830-8. PubMed ID: 9326252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of t(14;18) polymerase chain reaction-positive cells in highly purified CD34+ cells and their CD19 subsets in patients with follicular lymphoma.
    Voso MT; Hohaus S; Moos M; Haas R
    Blood; 1997 May; 89(10):3763-8. PubMed ID: 9160682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fate of contaminating t(14; 18)+ lymphoma cells during ex vivo expansion of CD34-selected hematopoietic progenitor cells.
    Widmer L; Pichert G; Jost LM; Stahel RA
    Blood; 1996 Oct; 88(8):3166-75. PubMed ID: 8874217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
    Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D
    Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Occult lymphoma cells prevalent in autologous marrow from non-Hodgkin's diffuse lymphoma.
    Yokoyama J; Fujimiya Y; Yamaguchi T; Shiga K; Saijo Y; Groveman DS; McBain JA; Suzuki Y; Ebina T
    Am J Hematol; 2003 May; 73(1):1-11. PubMed ID: 12701113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma.
    Negrin RS; Kusnierz-Glaz CR; Still BJ; Schriber JR; Chao NJ; Long GD; Hoyle C; Hu WW; Horning SJ; Brown BW
    Blood; 1995 Jun; 85(11):3334-41. PubMed ID: 7538824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts.
    Dreger P; Klöss M; Petersen B; Haferlach T; Löffler H; Loeffler M; Schmitz N
    Blood; 1995 Nov; 86(10):3970-8. PubMed ID: 7579368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A non-isotopic nested polymerase chain reaction method to quantitate minimal residual disease in patients with non-Hodgkin's lymphoma.
    Hétu F; Coutlée F; Roy DC
    Mol Cell Probes; 1994 Dec; 8(6):449-57. PubMed ID: 7700265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow.
    Gribben JG; Neuberg D; Barber M; Moore J; Pesek KW; Freedman AS; Nadler LM
    Blood; 1994 Jun; 83(12):3800-7. PubMed ID: 8204898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiplex PCR for the detection of BCL-1/IGH and BCL-2/IGH gene rearrangements--clinical validation in a prospective study of blood and bone marrow in 258 patients with or suspected of non-Hodgkin's lymphoma.
    Nyvold CG; Bendix K; Brandsborg M; Pulczynski S; Silkjaer T; Hokland P
    Acta Oncol; 2007; 46(1):21-30. PubMed ID: 17438702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eradication of polymerase chain reaction detectable immunoglobulin gene rearrangement in non-Hodgkin's lymphoma is associated with decreased relapse after autologous bone marrow transplantation.
    Zwicky CS; Maddocks AB; Andersen N; Gribben JG
    Blood; 1996 Nov; 88(9):3314-22. PubMed ID: 8896395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [BCL-2/IgH and IgH gene rearrangements in bone marrow mononuclear cells of patients with non-Hodgkin's lymphoma].
    Zhang XH; Liang Y; Wang GJ; Ruan EB; Fu R; Qu W; Liu H; Guan J; Song J; Wang HQ; Wu YH; Xing LM; Wang XM; Wang J; Li LJ; Shao ZH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):379-84. PubMed ID: 21518492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential high-dose therapy with peripheral-blood progenitor-cell support in low-grade non-Hodgkin's lymphoma.
    Haas R; Moos M; Karcher A; Möhle R; Witt B; Goldschmidt H; Frühauf S; Flentje M; Wannenmacher M; Hunstein W
    J Clin Oncol; 1994 Aug; 12(8):1685-92. PubMed ID: 7518860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
    Lemoli RM; Cavo M; Fortuna A
    J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting.
    Corradini P; Astolfi M; Cherasco C; Ladetto M; Voena C; Caracciolo D; Pileri A; Tarella C
    Blood; 1997 Jan; 89(2):724-31. PubMed ID: 9002976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.
    Papajík T; Jedlicková K; Kriegová E; Jarosová M; Raida L; Faber E; Hubácek J; Vondráková J; Pikalová Z; Indrák K
    Neoplasma; 2001; 48(6):501-5. PubMed ID: 11949845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment.
    Gribben JG; Freedman As; Woo SD; Blake K; Shu RS; Freeman G; Longtine JA; Pinkus GS; Nadler LM
    Blood; 1991 Dec; 78(12):3275-80. PubMed ID: 1742487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of tumor cells in purged bone marrow and peripheral-blood mononuclear cells by polymerase chain reaction amplification of bcl-2 translocations.
    Negrin RS; Pesando J
    J Clin Oncol; 1994 May; 12(5):1021-7. PubMed ID: 8164025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MBR rearrangement and P-glycoprotein expression are not independent prognostic factors like p53 protein in malignant lymphoma.
    Sun RX; Coste J; Segara C; Rousset T; Fabbro M; Rème T; Legouffe E; Klein B; Rossi JF
    Clin Lab Haematol; 1998 Apr; 20(2):87-94. PubMed ID: 9681218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.